Led · Seed · May 2026

Founded in 2025 and based in the United States, Melazyme develops a precision fermentation platform to produce specialty proteins and high-value biomolecules. Its pipeline includes brazzein and fermentation-derived melanin, which the company says can be produced with adjustable functional properties for different applications. Near-term commercial efforts are focused on the cosmetics sector, and Melazyme is already working with commercial partners and engaging with global manufacturers interested in melanin’s UV protection and pigmentation properties. The company is expanding into other high-value molecules where fermentation may offer advantages over conventional chemical processes. The newly raised seed capital is intended to scale the platform, increase production capacity, and support early commercial deployments and partner collaborations across consumer, industrial, and environmental markets.

Participated · Seed · Mar 2026

RyboDyn’s core products are RyboCypher™, a proprietary discovery engine combining deep sequencing of non-canonical RNAs with proteomic detection, and CypherAtlas™, a searchable atlas that integrates those data and powers foundational AI models. The company has expanded CypherAtlas™ to include data from roughly 1,000 patient tumor samples across 10 oncology indications, discovering more than 3 million conserved novel dark RNAs and empirically identifying over 80,000 cryptic peptides, including about 15,000 cancer-specific peptides. Many discovered cryptic proteins appear to contain functional domains and are localized to the cell surface or secreted, positioning them as candidate targets for targeted immunotherapies. RyboDyn is translating these discoveries into first-in-class antibody therapeutics internally and through partnerships, and plans to advance early-stage programs into IND-enabling studies. The company has licensed IP from OHSU’s Knight Cancer Institute, disclosed a strategic collaboration with Moffitt Cancer Center, and operates from Lilly Gateway Labs in San Diego.

Led · Seed · Dec 2025

Founded in 2024, Boston-based a2z Radiology AI is building an "intelligence layer" for medical imaging so clinicians can obtain radiologist-level insights on demand. Its first product, a2z-Unified-Triage, is the only FDA-cleared solution that simultaneously flags seven urgent findings on abdomen-pelvis CT scans, addressing the highest-volume CT category in the U.S. A prospective study unveiled at RSNA 2025 showed the software cut reporting time by 17.8 %, boosted radiologist confidence by 14.8 %, and lowered mental demand by 22.4 % while improving detection accuracy. By focusing on multi-condition analysis rather than single-pathology point solutions, the company aims to mirror how radiologists interpret studies in real practice. With U.S. abdomen-pelvis CT volume exceeding 20 million exams annually and radiologist shortages worsening, management believes its technology can meaningfully reduce wait times and missed findings. Fresh seed capital will fund partnerships with health systems, continued R&D, and a commercial rollout targeted for 2026. To date the firm has raised $4.5 million and has not disclosed revenue or user counts.

Participated · Seed · Nov 2025

Hepta leverages a proprietary liquid-biopsy-native transformer model that evaluates up to one billion cfDNA fragments per blood sample, uncovering subtle epigenetic patterns linked to organ-specific disease. Its first application targets metabolic dysfunction-associated steatohepatitis (MASH), where the assay achieved a diagnostic AUC of 0.86 and cut false positives threefold versus standard FIB-4 blood tests. The company’s MASH Atlas dataset, built with Duke University and other hepatology centers, shows strong concordance between cfDNA methylation and liver-tissue biology, validating the approach as a true ‘liquid biopsy’ for the liver. Founded by former Illumina, Grail and Google leaders, Hepta aims to replace invasive biopsies with routine blood draws and provide longitudinal intelligence for chronic disease management. Near-term plans include expanding clinical datasets, scaling the platform, achieving regulatory clearance and forging pharma partnerships. The platform’s attention-based architecture positions it to move beyond liver disease to other chronic conditions. Hepta recently secured $6.7 million in seed funding to finance these milestones.

Led · Equity · Sep 2025

Brineworks is an Amsterdam-based climate-tech company founded in 2023 by Gudfinnur Sveinsson and electrochemist Dr. Joseph Perryman. Its patented electrolyser captures CO₂ directly from the air while simultaneously generating substantial volumes of hydrogen, creating a cost-effective feedstock pair for sustainable aviation fuel and e-methanol. The system is designed to run intermittently, matching the variable output of wind and solar power without performance loss, which lowers operating costs and aligns with the falling price of renewable energy. This flexibility, combined with inexpensive materials, targets the current bottleneck in scaling e-fuels for hard-to-abate sectors like aviation and shipping. Aviation accounts for roughly 2.5 % and shipping over 3 % of global CO₂ emissions, providing a large market need for Brineworks’ solution. The company plans to scale its technology to pilot level with the new capital and aims for commercial readiness by late 2026. No revenue or user metrics have been disclosed.